WIDDER KENNETH J
Known title: DirectorCIK: 0001065168
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Competitors Tempus and Natera draw market attention. Recent news highlights increased activity by Personalis competitors. Tempus AI is expanding its cancer vaccine infrastructure with Moderna and Merck, while Natera faces rising competitive threats. These developments underscore the crowded nature of the precision medicine sector, providing context for Personalis's current trading position near its support levels.
Transaction History
| QDEL | ▲ Buy | Grant | 273 | $0 | 6/6/2026 | View on chart |
| QDEL | ▲ Buy | Grant | 910 | $0 | 6/6/2026 | View on chart |
| QDEL | ▲ Buy | Grant | 6,829 | $0 | 5/29/2026 | View on chart |
| PSNL | ▲ Buy | Grant | 6,250 | $0 | 5/12/2026 | View on chart |
| QDEL | ▲ Buy | Option Exercise | 7,021 | $111K | 11/25/2025 | View on chart |
| QDEL | ▼ Sell | Open Market | 4,026 | $112K | 11/25/2025 | View on chart |
| QDEL | ▲ Buy | Grant | 4,929 | $0 | 5/22/2025 | View on chart |
| QDEL | ▲ Buy | Grant | 512 | $0 | 5/18/2025 | View on chart |
| QDEL | ▲ Buy | Grant | 153 | $0 | 5/18/2025 | View on chart |
| QDEL | ▲ Buy | Option Exercise | 3,333 | $93K | 7/19/2024 | View on chart |
| QDEL | ▲ Buy | Grant | 2,416 | $0 | 5/24/2024 | View on chart |
| QDEL | ▲ Buy | Grant | 328 | $0 | 5/12/2024 | View on chart |
| QDEL | ▲ Buy | Grant | 98 | $0 | 5/12/2024 | View on chart |
| QDEL | ▲ Buy | Grant | 2,248 | $0 | 6/6/2023 | View on chart |
| QDEL | ▲ Buy | Grant | 315 | $0 | 5/14/2023 | View on chart |
| QDEL | ▲ Buy | Grant | 1,050 | $0 | 5/14/2023 | View on chart |
| QDEL | ▲ Buy | Grant | 18,684 | — | 5/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
QuidelOrtho Reports Q2 2026 Results and New IR Lead
QuidelOrtho released its second-quarter 2026 earnings, with reports noting that profit margins have recovered while cash levels remain a point of discussion. The company also announced the appointment of Sanjeev Sharma as Vice President of Investor Relations. These updates provide context for the stock's current position within its 52-week range.
QuidelOrtho Reports Q2 2026 Results and New IR Lead. QuidelOrtho released its second-quarter 2026 earnings, with reports noting that profit margins have recovered while cash levels remain a point of discussion. The company also announced the appointment of Sanjeev Sharma as Vice President of Investor Relations. These updates provide context for the stock's current position within its 52-week range.